Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 1, 2012

Islet Sciences to Pick Up DiaKine Therapeutics

  • Islet Sciences, a company engaged in transplantation therapy for patients with diabetes, entered into a share exchange agreement to acquire DiaKine Therapeutics (DTI). DTI has a parenteral drug in early clinical development and a preclinical pipeline of oral therapies.

    “DiaKine's drugs have the potential to reshape the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease,” according to John Steel, chairman and CEO of Islet Sciences.

    “Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes, which we believe has a total addressable market of approximately $13 billion.” Islet Sciences’ transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection of islet cells.

    DTI's most clinically advanced drug, Lisofylline (LSF), works at the cellular level by improving the function of insulin-producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself, the company explains. This autoimmune action is the cause of type 1 diabetes and latent autoimmune diabetes in adults (LADA).

    LSF as an IV treatment is in a Phase II trial as an adjunct therapy to islet cell transplants. It is also being studied in a separate Phase I study involving newly diagnosed type 1 diabetes patients as a subcutaneous formulation.

    DiaKine also has a slew of next-generation of orally bioavailable immune modulators. DiaKine reports that several lead compounds have been identified for further development. For example, DT 22669 is being evaluated as a therapy for LADA and insulin-dependent type 2 diabetes, and DT 23552 has been identified for its potential against diabetic nephropathy and retinopathy.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »